4-Year Survival With Durvalumab Post Chemoradiotherapy in Stage III NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brief Report: Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - An Update From the PACIFIC Trial
J Thorac Oncol 2021 Jan 18;[EPub Ahead of Print], C Faivre-Finn, D Vicente, T Kurata, D Planchard, L Paz-Ares, JF Vansteenkiste, DR Spigel, MC Garassino, M Reck, S Senan, J Naidoo, A Rimner, YL Wu, JE Gray, M Özgüroğlu, KH Lee, BC Cho, T Kato, M de Wit, M Newton, L Wang, P Thiyagarajah, SJ AntoniaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.